Ascentage Pharma Group International (AAPG) Receivables - Net (2023 - 2025)

Ascentage Pharma Group International (AAPG) has reported Receivables - Net for 3 consecutive years, with $35.7 million the latest figure, recorded in Q4 2025.

• Quarterly Receivables - Net rose 208.1% year-over-year to $35.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $35.7 million (up 208.1% YoY) and the FY2025 annual result came in at $36.2 million, up 217.56% from the prior year.
• Receivables - Net grew to $35.7 million in Q4 2025 per AAPG's latest filing, from $10.9 million in the prior quarter.
• Over the last five years, Receivables - Net for AAPG reached as high as $35.7 million in Q4 2025 and fell as low as $10.9 million in Q2 2025.
• A 3-year average of $19.6 million and a median of $15.9 million in 2023 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2024 — Receivables - Net slumped 42.88% — and 2025, when it soared 208.1%.
• Year by year, Receivables - Net stood at $20.3 million in 2023, then slumped by 42.88% to $11.6 million in 2024, then surged by 208.1% to $35.7 million in 2025.
• According to Business Quant data, Receivables - Net over the past three periods registered $35.7 million, $10.9 million, and $11.6 million for Q4 2025, Q2 2025, and Q4 2024 respectively.